TO evaluate the effects of deglycosylated ricin A-chain (dgA) immunotoxins against disseminated Hodgkin's lymphoma, we used RFT5.dgA (CD25) and IRac.dgA (70 kD) to treat L54OCy Hodgkin cells in severely immunodeficient SClD mice. In this model, more than 90% of the animals developed multiple lymphomas in various organs such as the lymph nodes, liver, bone marrow, and extranodal sites that killed untreated animals after a mean survival time (MST) of 36.3 days. A single intraperitoneal injection of 8 pg of either immunotoxin rendered 95% (RFT5.dgA) and 93% (IRac.dgA), respectively, of mice tumor-free when ap-EVERAL SECOND generation immunotoxins constructed by linking monoclonal antibodies (MoAbs) via the sterically hindered SMPT linker to deglycosylated ricin A-chain (dgA) have been shown to be extremely potent in animal models against leukemias and Immunotoxins against CD19 and CD22 are currently being tested in phase 1/11 trials in patients with refractory nonHodgkin's l y m p h~m a .~.~ One of the most frequently diagnosed lymphomas, Hodgkin's disease (HD), has recently been recognized as a potential target for immunotoxin treatment for several reasons. First, the Hodgkin/Reed-Sternberg (H-RS) cells express large numbers of surface markers such as CD25 and CD30 that are present only on a small minority of normal lymphoid cells. Second, the number of H-RS cells that has to be destroyed is small because the rnajority of cells in Hodgkin's lymphomas are nonmalignant reactive cells. Third, Hodgkin's tumors are well vasculari~e d ,~ suggesting that access of the immunotoxin to the target cells should be easier than it is, for example, in solid tumors. In addition, exceptional potency of ricin A-chain immunotoxins against L54OCy Hodgkin cells both in vitro6 and in vivo' has been shown. In recent phase I clinical trials, HD patients have responded well to therapy with immunotoxins constructed by linking Saporin-6 to a CD30 MoAb' or by fusing interleukin-2 (1L-2) with diphtheria-toxin. ' From a panel of more than 40 MoAbs tested, RFT5 
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(CD25) was found to yield one of the most potent ricin Achain immunotoxins produced so far, combining high specificity against H-RS cells in vitro with potent antitumor effects against solid Hodgkin's tumors in nude mice." To optimize schedules and strategies of immunotoxin therapy in humans, we developed a model of disseminated HD in mice with severe combined immunodeficiency (SCID)." We describe here the antitumor effects of RFr'5.dgA and an immunotoxin that binds to an unclustered 70-kD antigen on H-RS cells. IRac.dgA, against disseminated human HD in this model.
MATERIALS AND METHODS
Muteria1.s. Tissue culture medium RPMI 1640 and fetal calf serum were purchased from GIBCO-Biocult, Ltd (Paisley, UK). Sepharose G25 (fine grade), Sephacryl S200 HR, and blue Sepharose CLdB were obtained from Pharmacia Ltd (Uppsala, Sweden). Falcon tissue culture flasks were purchased from Becton Dickinson (Oxnard, CA). Human Cot-l DNA was from GIBCO BRL, Life Technologies, Inc (Gaithersburg, MD). ~' [ c x~~P I -~A T P , L-[4,S3H]-Leucine, and Hybond-N-Transfer membranes were obtained from Amersham International (Braunschweig, Germany). Random primed DNA-Labeling Kit and RNase-A were purchased from Boehringer Mannheim (Mannheim, Germany). Proteinase K and Denhardt's solution were from Sigma (St Louis, MO). The Cellfree 1L-2R Test Kit was purchased from T Cell Diagnostics, Inc (Cambridge, MA). Ber-HZ antibody, biotinylated rabbit antimouse MoAb (E 4 I3), and a streptavidin-biotin-complex labeled with alkaline phosphatase (K 391) were from Dako Diagnostics (Hamburg, Germany). New Fuchsin was obtained from Serra Feinbiochemica (Heidelberg, Germany).
C&. The cell line L54OCy was maintained in RPMI 1640 supplemented with 10% (vol/vol) heat-inactivated fetal calf serum, 2 mmol/L L-glutamine, 50 IU/mL penicillin, and 50 pg/mL streptomycin. Cells were cultured in an atmosphere of 5% CO2 and humidified air. The L54OCy is a mutant of the L540 cell line,12 which has been shown to have superior take rates in mice as compared with the parental L540."
Chinese hamster ovary (CHO) cells" grew as adherent cells in the same medium. For the preparation of cell suspensions they had to be detached by adding trypsin-EDTA solution (10%).
Antibodies. The MoAbs used in this study were RFT5 (IgG I ),Io IRac and Ber-H2 (IgGl).15 RFTS recognizes the CD25 antigen, lRac has been reported to recognize a 70-kD antigen on Hodgkin and Reed-Sternbergcells,'6 and Ber-H2 binds to the CD30 antigen. The mouse MoAb OX7 (IgG1) recognizing the mouse Thy l . 1 antigen was used as nonspecific isotype control. Immunotoxins. Two different immunotoxins, RIT5.dgA and IRac.dgA, were prepared as described elsewhere." In brief, the MoAbs were treated with the heterobifunctional linker, 4-succinimidyl-oxycarbonyl-a-methyl-a-(2-pyridyldithio) toluene (SMFT) to introduce an average of 1.7 activated disulfide groups per molecule of antibody. The derivatized protein was separated from unreacted material by gel chromatography on a Sephadex G-25 column and mixed with freshly reduced deglycosylated ricin A-chain." After 72 hours, residual thiol groups were inactivated with 0.2 mmol/ L cysteine. The immunotoxin preparation was then purified from unreacted ricin A-chain, cysteine, and high molecular weight aggregates on a Sephacryl S200 HR column. Finally, free antibody was removed by chromatography on a Blue Sepharose CLdB column." Cytotoxicity assays. L54OCy Hodgkin cells in complete medium were distributed into 96-well plates with each well containing 2 X IO4 cells in 100 pL. Immunotoxins were added to give final concentrations ranging from 1 X IO-* to 1 X IO-" mol/L. The plates were incubated for 24 hours at 37°C in an atmosphere of 5% CO2 in humidified air, pulsed with 1 pCi/well ['HI-leucine, and incubated for another 24 hours. The cells were then harvested onto glass fiber filters using a Titertek cell harvester and the incorporated [3H]-leucine was measured by liquid scintillation (Beckmann, LS/ 80 I). The concentration required to achieve a 50% reduction of protein synthesis relative to untreated control cultures was calculated.
Animals. The SCID mice were obtained from our own colony and maintained under sterile conditions. Antibiotic prophylaxis was not provided.
Establishment of the tumor model and antitumor experiments.
Adult 4-to 6-week-old SCID mice were injected intravenously via the tail vein with 1 X IO' L54OCy Hodgkin cells suspended in 400 pL of phosphate-buffered saline (PBS) containing 0.2% bovine serum albumine (BSA). Vital signs were recorded daily, and weight was measured once per week. Four to 6 weeks after inoculation of the tumor cells, untreated animals developed signs of progressive disease including weight loss, ruffled fur, and inactivity. The SCID mice were then killed. After macroscopic examination, different organs, including lymph nodes, liver, spleen, lung, kidneys, thymus, intestine, caecum, muscle, and extranodal tumors, were either fixed in 10% buffered formalin or snap-frozen in liquid nitrogen. Cytocentrifuge slides were prepared from bone marrow extracted from the tibiae. Mouse serum was obtained by heart puncture and centrifugation of the blood. SCID mice with elevated Ig levels were identified using an enzyme-linked immunosorbent assay (ELISA)" and excluded from further studies.
For treatment experiments, the mice were randomly divided into groups of five or six. One day after inoculation of L54OCy Hodgkin cells, the SCID mice received a single intraperitoneal (IP) injection of immunotoxin or antibody in a volume of4OCl pL PBS containing 0.2% BSA. The dose of immunotoxin (48 pg of total protein corresponding to 8 pg of ricin A-chain) represented the same proportion of the LDSo (50% lethal dose) of RFT5.dgA and 1Rac.dgA in nude mice.' The doses of unconjugated MoAbs (40 pp) matched those in the immunotoxins.
All animals were killed after 6 weeks and examined for signs of tumor growth by gross macroscopy, immunohistopathology, and dot blotting of extracted DNA from various organs.
TO evaluate the effects of immunotoxin treatment on the mean survival time (MST), groups of 10 SCID mice were treated with RlT5.dgA as indicated above. RlT5-and PBS-treated animals served as controls.
Irnmunohistopathology. Organs were fixed in 10% buffered formalin, paraffin-embedded, sectioned, and then stained with hematoxylin and eosin or Giemsa's solution for microscopic examination. Immunohistochemistry was performed using the streptavidinbiotin-complex method (ABC method) described previously.2' In brief, the sections were digested with trypsin followed by incubation with the CD30 MoAb Ber-H2 (dilution 1:50) for 30 minutes at room temperature. After brief washes in Tris-buffered saline, the slides were incubated with a biotinylated rabbit antimouse MoAb [F(ab) fragments, E 4 13, dilution I :400,30 minutes]. After washing, the slides were incubated with streptavidin-biotin-complex labeled with alkaline phosphatase (K 391) for 30 minutes. After another wash, the alkaline phosphatase reaction was developed with the New Fuchsin method. The slides were counterstained with Haemalaun and mounted.
Cytocentrifuge slides of bone marrow were fixed in 100% aceton and stained with CD25, CD30, and lRac MoAbs using the APAAPtechnique that has been described in detail elsewhereT2
DNA isolation and dot-blot analysis. For DNA isolation, various mouse organs were grounded in a cold mortar. The solution was resuspended in 5 mL of lysis buffer ( 1 % sodium dodecyl sulfate One hundred nanograms of each sample was transferred to the Hybond-N-Transfer membrane. The samples were air-dried overnight and then prehybridized for 24 hours at 42°C in a solution containing 50% formamide, I% SDS, SSPE (0.75 mol/L NaCl, 50 mmol/L NaH2P04.H20, 5 mmol/L Na2EDTA, pH 7.4), Denhardt's solution (0.1% BSA, 0.1% ficoll, 0.1% polyvinylpyrrolidone), 50% dextran sulfate, and 50 &mL salmon sperm DNA. Hybridization was performed with the prehybridization buffer and 100 ng of a [32P]-labeled cot-1 DNA probe overnight at 42'C. Cot-1 DNA23 was obtained from human placental DNA and enriched for repetitive DNA sequences such as the A h I and Kpn 1 family members. The transfer membrane was washed at high stringency and autoradiographed.
The percentage of the human DNA present in the mice organs was estimated by computerized densitometry. The following human-hamster DNA mixtures were used as controls: 50% human-50% hamster, 25% human-75% hamster, 5% human-95% hamster, 0.5% human-99.5% hamster, 0.05% human-99.95% hamster, and 0.005% human-99.995% hamster.
Establishment andcharacterization oJrecultures. Tumors were removed under sterile conditions, rinsed in complete medium, and finely minced with a scalpel. Tumor cell containing medium was then transferred into Falcon tissue flasks with a syringe and incubated in complete medium. Cytocentrifuge slides were prepared from the recultured cells and stained with IRac, RFT5, and Ber-HZ MoAbs, respectively, using the APAAP-technique (see above). When the cultures appeared to be homogenous for L54OCy cells (about 2 weeks after tumor excision), the cells were checked for antigen expression by FACS analysis using standard techniques described elsewhere" and retreated with immunotoxins in vitro (see Cytotoxicity Assays).
IL-2R ELISA. Serum of tumor-bearing SCID mice was examined for circulating IL-2R complexes using a standard IL-2R ELISA. Serum from healthy animals served as controls. Slafi~rica/ana/~sis. To compare different treatment modalities, the animals were killed 6 weeks after tumor cell inoculation and staged according to the extent of tumor burden. Mice with tumor growth restricted to the lymph nodes were scored as stage 1. Liver involvement was scored as stage I1 and additional extranodal disease as stage 111. Stage IV was defined as extended disease with the involvement of lymph nodes, liver, and/or extranodal disease plus additional bone marrow involvement.
The different scores per group were added and divided by the number ofanimals per group, resulting in an average staging index per group. The statistical significance was determined by the Wilcoxon-Mann-Whitney U-test. The survival data were tested for statistical significance using the Cox-Mantel test. proximately 4 weeks in untreated animals. Animals were killed after 6 weeks. Lymphomas were observed in lymphatic organs like lymph nodes (92%; Fig IA) , liver (57% ;   Fig 1 B) , and bone marrow (8%; Fig I C) . Lymph nodes involved included axillary, inguinal, cervical, paraaortic, caecal, mesenteric, iliac, gluteal, renal. and portal nodes. The human Hodgkin's lymphomas grew as distinct white nodules of solid consistency and variable size. In addition to the nodal tumor formation, extranodal tumor growth was observed in bones (8 animals). kidneys (6 animals), testes (2 animals), lungs ( 2 animals), and muscle ( 1 animal). Hindleg paresis caused by enlarged gluteal lymph nodes adjacent to the sciatic nerve was observed in 3 of 37 animals. In contrast to the growth pattern of Hodgkin's lymphomas in humans, there was no evidence of spleen involvement. Average spleen size ( I 2 x 3 X 1 mm) of tumor-bearing animals was similar to the spleen size of healthy SClD mice. (Fig 2) showed that as few as 1 X los L54OCy can be detected by radiographic dot-blotting with DNA probes enriched for repetitive human DNA sequences. Table 1 shows a comparison of the different methods identifying human L54OCy Hodgkin cells in SCID mice. There was a strong correlation between gross macroscopy, immunohistology, and detection of human DNA in organs infiltrated with L54OCy cells. In about 5% of animals that had been treated with immunotoxins, marginally enlarged lymph nodes were detected and analyzed with the methods indicated above. These lymph nodes were subsequently classified as reactive mouse lymphoma not containing human tumor cells.
RESULTS

Growth
Histologically, the tumors appeared as large cell anaplas-
Characterization ofimrntmoroxins. The immunotoxins used in the present study were generated by linking MoAbs of the lgGl subclass to deglycosylated ricin A-chain. Both RFT5.dgA (CD25) and IRac.dgA (unclustered 70 kD) had little cross-reactivity with normal human tissues when tested on cryostat sections: RFT5.dgA binds to a few activated lymphocytes and macrophages in lymphoid organs, 1Rac.dgA had only very minor crossrea~tivity.~.'~ The two immunotoxins were extremely powerful against L54OCy Hodgkin cells in vitro (Fig 3) . The concentration at which the protein synthesis of L54OCy cells is inhibited by 50% (ICso) is6 X IO-'* mol/Lfor RFTS.dgA, which is identical to that ofwhole ricin under the same experimental conditions. RFT5.dgA is the most potent immunotoxin against HD described so far. IRac.dgA is the second most potent immunotoxin, with an ICso of 1 X lo-'' m01/L.~ Effects of immmoroxin treatment in SCID mice. To compare different treatment modalities, the extent of tumor infiltration was scored according to the pathologic staging. The data of the treatment experiments are summarized in Table 2 . In the untreated control group (n = 37), there were The results for SCID mice treated with 1Rac.dgA were similar. After treatment on day l, only 1 of 15 mice had bone marrow infiltration with L54OCy cells, resulting in 93% complete remissions and a staging index of 0.26 ( P < .oooo 1 ).
Effect ofimmunotoxin treatment on MST oftumor-bearing SCID mice. Groups of 10 SCID mice were treated with RFTS.dgA, RFT5, and PBS, respectively, l day after tumor challenge with L54OCy Hodgkin cells. As illustrated in Fig  4, the MST ofthe PBS-treated control group was 36.3 (+ 1.6) days. Upon macroscopical examination, all animals in this group had extended tumor masses. Treatment with the RFT5 antibody alone extended the MST by 1 1.3 (k5.5) days (P = ,0002) without inducing complete remissions. In contrast, 7 of 10 mice treated with 8 pg of RFT5.dgA 1 day after the inoculation of L54OCy cells were in continuous complete remission more than 180 days after treatment. This result is highly statistically significant ( P < .OOOOl).
One animal treated died for unknown reasons on day 68 without exhibiting evidence oftumor growth. The other two animals treated with RFT5.dgA died from progressive lymphoma growth in lymph nodes, liver, kidney, and muscle on days 82 and 93, respectively. Recultures of these tumors showed that most malignant cells expressed the CD30 and the IRac (70 kD) antigen similar to the parental L54OCy
Hodgkin cells. In contrast, more than 70% of the recultured cells were CD25-. In cytotoxicity assays, these sublines were less sensitive to RFT5.dgA than the original L54OCy line. t Extranodal sltes included muscle, jaw, kidney, scapula, and testis gens (cocktail) on L54OCy cells, two groups of a total of 1 1 SCID mice were treated with a mixture of 4 pg 1Rac.dgA and 4 @g RFT5.dgA 1 day after the inoculation of L54OCy cells. The treatment with the immunotoxin cocktail induced lasting complete remissions in all SCID mice resulting in a staging index of 0. No L54OCy Hodgkin cells were detected by means of gross examination, immunohistopathology, and DNA dot-blotting ( Table 2 ). The effect of the immunotoxin cocktail was highly statistically significant as compared with the control group (P < .OOOOl) but not superior to single immunotoxin treatment.
Eflect ojimmunotoxin treatmen1 on mice with larger tumor burden. A group of 11 SCID mice was treated with RFT5.dgA 12 days after the inoculation of L54OCy cells to test the antitumor potency of RFT5.dgA on larger tumor burdens. Upon death on day 42,5 of 1 1 mice had no detectable L54OCy tumors, resulting in a complete remission rate of 46% (Table 2 ) and a staging index of 1.09. These results were statistically significant (P = .0307), but less pronounced compared with the earlier schedule in which the animals were treated 1 day after tumor challenge.
E&t
oftreutment with the RFT5 und IRac antibodies. Treatment of SCID mice with the RFTS or IRac MoAbs alone did not result in statistically significant antitumor effects. There were no complete remissions in the IRactreated group (n = 5; staging index = 1.4). In the RFT5-treated group, 8 of 9 animals developed lymphomas, resulting in a staging index of 1.56. The effects of the antibodies alone against L54OCy cells in SCID mice might be related to the activity of natural killer (NK) cells. Pretreatment of SCID mice with anti-asialo GM1 antibodies has been reported to induce an effective NK-cell depletion in SCID mice, which abrogates the antitumor effects of antibody treatment in this Soluble CD25 levels in SCID mice with disseminated Hodgkin S lymphoma. Serum samples of SCID mice with disseminated L54OCy Hodgkin's tumors and healthy controls were evaluated for circulating IL-2 receptor (sCD25) using a standard ELISA method. As shown in Fig 5, mice examined 1 day after the injection of 1 X IO' L54OCy Hodgkin cells had detectable sCD25 levels averaging 105 U/mL (range, 54 to 155 U/mL; n = IO). When measured 42 days after injection of tumor cells, animals with Hodgkin's lymphomas limited to the lymph nodes (stage I) had average sCD25 levels of 403 U/mL (range, 175 to 5 15 U/mL; n = 8). By contrast, animals with extended disease involving liver and extranodal sites had average sCD25 levels of 1,095 U/mL (range, 305 to 2,125 U/mL; n = 10). These results suggest that the amount of sCD25 shed from the L54OCy Hodgkin cells is correlated with the tumor burden.
DISCUSSION
The major finding to emerge from this study is that immunotoxins constructed with deglycosylated ricin A-chain and the SMPT linker have potent antitumor effects against disseminated Hodgkin's lymphomas in SCID mice. A single injection of either immunotoxin, RlT5.dgA (CD25) or IRac.dgA (70 kD, unclustered), 1 day after challenge with 1 X IO7 L540Cy cells rendered more than 90% of animals tumor-free when examined 42 days after treatment. The MST of mice treated with RFT5.dgA was extended by more than 120 days as compared with 36.3 days of the PBStreated controls (P < .0000 I).
Several animal models have been evaluated to study the biology of human H D in suitable hosts. Poor take rates have always been one of the major obstacles. To achieve reproducible results and reliable take rates, nude mice were inoculated subcutaneously12 or intracraniallyz5 with immortalized cell lines established from patients with HD. In a previous study, we reported the take rates of solid tumors induced by subcutaneous injection of L540Cy Hodgkin cells to exceed 90% in B-, T-, and NK-cell-deficient "triple beige mice.'17 The severely immunodeficient SCID mouse is currently being evaluated as a model of disseminated human HD." In SCID mice, L540Cy Hodgkin cells grow progressively in various organs, including lymph nodes, liver, bone marrow, and extranodal organs, thus mimicking the growth pattern of the disease in humans (Fig I A through  D) . The only exception is the lack of spleen involvement, which is probably caused by the different anatomy of the lymphatic system in human and mouse spleens. Histologically, the tumors appeared as LCA lymphomas containing a majority of large Hodgkin cells. Unlike the results found in most human H D subtypes, reactive bystander-cells were rare, suggesting that the human cytokines produced by the H-RS cells do not recruit murine bystander cells.
To assess the effects of ricin A-chain immunotoxins against disseminated L540Cy lymphomas, we used different detection methods: gross macroscopy, immunohistopathology, and dot-blotting of extracted DNA. These methods showed a good degree of correlation in detecting L540Cy cells in organs infiltrated ( Table 1) . In most cases, lymphomas identified by gross macroscopy were subsequently confirmed by immunohistology and dot-blotting to consist of human L540Cy cells. In older SCID mice, some marginally enlarged lymph nodes were classified as reactive mouse lymphoma not containing human tumor cells.
Mice challenged with L54OCy cells were treated 1 day later with RFT5.dgA and 1Rac.dgA immunotoxins containing 8 pg of A-chain, respectively. Animals were killed 42 days later, at a time when most untreated mice with disseminated L540Cy Hodgkin's tumors would have died of progressive disease. The treatment results were highly statistically significant as compared with the PBS-or MoAbtreated control groups (Table 2 ): RFT5.dgA induced complete remissions in 95% of animals (22 of 23) and 1Rac.dgA resulted in 93% complete remissions (14 of 15). The MST of SCID mice treated in additional experiments with RFT5.dgA 1 day after tumor challenge was greater than 150 days as compared with 36 days in a PBS-treated control group.
Two mice treated with RFT5.dgA died of progressive lymphoma growth on days 82 and 93, respectively (Fig 4) . Macroscopic and immunohistologic examinations showed L540Cy tumor growth in lymph nodes, liver, kidney, and muscle. Analyses of recultures showed that most ofthe Hodgkin cells recultured lacked the CD25 antigen. Obviously, antigen-negative mutants had survived the initial treatment and caused relapses. Similar observations have been made in an AKR mouse model in which Thy 1.1-negative mutants induced death of 20% of mice treated with an immunotoxin against the Thy 1.1 antigen.17 Treatment with a combination of two immunotoxins ("cocktail") should reduce the likelihood of mutant cell escape. In SCID mice, an immunotoxin cocktail consisting of RFT5.dgA and 1Rac.dgA rendered 100% of SCID mice tumor-free when examined 42 days after treatment (1 1 of 1 1 ; Table 2 ). Because these results did not show statistical significance when compared with single immunotoxin treatment, we are currently determining the long-term survival data of SCID mice for both immunotoxins and immunotoxin cocktails. The results obtained with RFT5.dgA applied I2 days after tumor challenge were inferior to the treatment on day 1 (46% v 95% complete remissions), suggesting that the antitumor effect of immunotoxin treatment might, at least in part, depend on the number of L54OCy cells present. AnFor personal use only. on October 26, 2017. by guest www.bloodjournal.org From other factor is probably the formation of solid L54OCy tumors in the animals 12 days after the initial injection, which are less accessible to the bloodstream of intravenously administered drugs. 27 The impressive antitumor effects observed against disseminated human L54OCy tumors in this study parallel those observed against solid Hodgkin's tumors in nude Possible reasons are the high sensitivity of Hodgkin's lymphomas to immunotoxin treatment and the use of second generation immunotoxins that, in contrast to their predecessors, have potent antitumor effects in v~v o . ' *~~~ In SCID mouse models, similar constructs have produced pronounced effects against disseminated human B-cell lymphoma' and T-cell leukemia.2 Taken together, these results point towards a possible clinical use of immunotoxins against lymphomas in humans. Although cures in patients with massive tumor burdens are unlikely to occur, immunotoxins might be useful as an additional treatment modality in high-risk patients to kill residual tumor cells. This view is supported by the results of a recent study in which 3 of4 heavily pretreated patients who had residual tumor cells after autologous bone marrow transplantation were rendered tumor-free by treatment with an anti-CDI 9 ricin Achain i r n m u n o t~x i n .~~ Importantly, these results were obtained with a sensitive PCR method in which as few as I lymphoma cell in 106 normal cells can be dete~ted.~'
One of the possible problems using immunotoxins against antigens that are being shed from the cell surface is the binding of immunotoxin to the circulating antigen resulting in a reduced antitumor effect. Our results suggest that shedding of sCD25 in SCID mice is dependent on the tumor cell mass (Fig 5) . This has been described for Hodgkin's lymphoma in although it might be impossible to differentiate between sCD25 shed from H-RS cells and sCD25 shed from activated lymphocytes. Because the major strength of immunotoxins in humans will be to treat residual tumor cells after standard chemotherapy rather than bulky disease, the amount of sCD25 is expected to be rather small in these patients.
In summary, ricin A-chain immunotoxins have potent antitumor effects against disseminated Hodgkin's lymphomas in SCID mice. Currently, we are using this model to further optimize the immunotoxin treatment strategies including scheduling and dosing. These experiments parallel the ongoing clinical trial of RFT5.dgA in patients with resistant HD.
